Although antibiotics are an effective treatment option, evidence indicates that fecal microbiota transplant holds promise in treating refractory or recurrent C difficile infections.
A patient’s neurological symptoms diminished when he discontinued a biosimilar and started various new treatments.
Researchers found a 27% heightened risk of cardiovascular disease for individuals with celiac disease compared with those who didn’t have the condition.
Zolbetuximab treatment reduced risk of death by 25% compared to placebo.
An organ transplant is a known risk factor for C. difficile infection, however, data are lacking on how the infection affects those who underwent an intestinal transplant.
The popularity of intermittent fasting, or time-restricted eating patterns, may not help control weight as well as other dieting methods.
It is too early to know how patients could potentially change their microbiome to reduce their diabetes risk.
The subcutaneous formulation could enhance treatment options by providing high consistency in drug exposure and a convenient administration method.
Live-jslm (Rebyota; Ferring Pharmaceuticals) is indicated for the prevention of recurring Clostridioides difficile infection among patients 18 years of age and older after an antibiotic treatment.
Like using good nutrients to grow tomatoes in the soil, good nutrients and diverse microbes are important for our good gut health, or our gut's "garden," said a leading researcher.
The pharmacologic options for irritable bowel syndrome are based on the adverse effect profile, cost, and predominant symptoms.
Adults with type 2 diabetes may benefit from eating more whole grains, fish, fiber, and omega-3 fatty acids in their diet, which could lower co-morbidities associated with death.
The FDA approved Azurity Pharmaceutical’s omeprazole and sodium bicarbonate for oral suspension to treat benign gastric ulcers and it is predicted to reach commercial markets by next year.
The first step to reducing recurrent C. difficile infections is prevention.
Most individuals can manage the discomfort of GERD with lifestyle changes and OTC medications.
A significantly greater proportion of patients with Crohn disease achieved both primary endpoints with overall safety results generally consistent with the known safety profile of risankizumab.
Despite presenting in only 18% of cases, 16% of all COVID-19 patients only present with gastrointestinal symptoms.
The FDA granted breakthrough therapy designation to dupilumab in September 2020, for the treatment of patients age 12 years and older with eosinophilic esophagitis.
Educate patients about the appropriate and safe use of gastrointestinal products and direct them to seek further medical care when warranted.
Like diabetes, Inflammatory bowel disease may also be linked to a high-fructose diet.
Pharmacists can play an integral role in collaborating with physicians to manage patient therapy.
Nizatidine Oral Solution is a prescription oral product used for the short-term treatment and maintenance therapy of ulcers and for the treatment of esophagitis and associated heartburn due to GERD.
Why was a patient prescribed something normally used for stomach problems to help her produce breastmilk?
Generic products featured in the April 2020 issue.
A survey conducted between March 30 to April 6 by InsightRx found that implementing the new vancomycin guidelines into the pharmacy community is as important as the coronavirus disease 2019 (COVID-19) in the healthcare system.
